Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function – evidence of interconversion

Por Hamrén, Bengt, Ericsson, Hans, Samuelsson, Ola, Karlsson, Mats O
Publicado em 2008

Application of the integrated glucose–insulin model for cross‐study characterization of T2DM patients on metformin background treatment

Por Parkinson, Joanna, Hamrén, Bengt, Kjellsson, Maria C., Skrtic, Stanko
Publicado no Br J Clin Pharmacol (2016)

Model selection and averaging of nonlinear mixed-effect models for robust phase III dose selection

Por Aoki, Yasunori, Röshammar, Daniel, Hamrén, Bengt, Hooker, Andrew C.
Publicado no J Pharmacokinet Pharmacodyn (2017)

Exposure–response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation

Por Lip, Gregory Y. H., Rasmussen, Lars H., Olsson, S. Bertil, Jensen, Eva, Hamrén, Bengt, Eriksson, Ulf G., Wåhlander, Karin
Publicado no Br J Clin Pharmacol (2015)

Requirements for multi-level systems pharmacology models to reach end-usage: the case of type 2 diabetes

Por Nyman, Elin, Rozendaal, Yvonne J. W., Helmlinger, Gabriel, Hamrén, Bengt, Kjellsson, Maria C., Strålfors, Peter, van Riel, Natal A. W., Gennemark, Peter, Cedersund, Gunnar
Publicado no Interface Focus (2016)